The Signature of SARS-CoV-2-related Genes Predicts the Immune Therapeutic Response and Prognosis in Breast Cancer

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2024 Nov 1

PMID 39482662

Authors

Ruizhi Fu

Yequn Chen

Jiajing Zhao

Xiaojun Xie

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an exceptionally contagious single-stranded RNA virus with a strong positive contagion. The COVID-19 pandemic refers to the swift worldwide dissemination of SARS-CoV-2 infection, which began in late 2019. The COVID-19 epidemic has disrupted many cancer treatments. A few reports indicate that the prevalence of SARS-CoV-2 has disrupted the treatment of breast cancer patients (BCs). However, the role of SARS-CoV-2 in the occurrence and prognosis of BC has not been elucidated. Here, we applied bioinformatics to construct a prognostic signature of SARS-CoV-2-related genes (SCRGs). Specifically, weighted gene co-expression network analysis (WGCNA) was utilized to extract co-expressed genes of differentially expressed genes (DEGs) in breast cancer and SCRGs. Then, we utilized the least absolute shrinkage and selection operator (LASSO) algorithm and univariate regression analysis to screen out three hub genes (DCTPP1, CLIP4 and ANO6) and constructed a risk score model. We further analyzed tumor immune invasion, HLA-related genes, immune checkpoint inhibitors (ICIs), and sensitivity to anticancer drugs in different SARS-CoV-2 related risk subgroups. In addition, we have developed a nomination map to expand clinical applicability. The results of our study indicate that BCs with a high-risk score are linked to negative outcomes, lower immune scores, and reduced responsiveness to anticancer medications. This suggests that the SARS-CoV-2 related signature could be used to guide prognosis assessment and treatment decisions for BCs.

References

Sharma V, Sharma A, Punj V, Priya P . Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer. Semin Cancer Biol. 2019; 59:133-146. DOI: 10.1016/j.semcancer.2019.08.005. View

Swainston J, Chapman B, Grunfeld E, Derakshan N . COVID-19 Lockdown and Its Adverse Impact on Psychological Health in Breast Cancer. Front Psychol. 2020; 11:2033. PMC: 7476556. DOI: 10.3389/fpsyg.2020.02033. View

Yang S, Polley E, Lipkowitz S . New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016; 45:87-96. PMC: 7436195. DOI: 10.1016/j.ctrv.2016.03.004. View

Zhao J, Luo Z, Fu R, Zhou J, Chen S, Wang J . Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma. Eur J Med Res. 2023; 28(1):571. PMC: 10698993. DOI: 10.1186/s40001-023-01535-3. View

Geeleher P, Cox N, Huang R . pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014; 9(9):e107468. PMC: 4167990. DOI: 10.1371/journal.pone.0107468. View

Ibrahim S, Gadalla R, El-Ghonaimy E, Samir O, Mohamed H, Hassan H . Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer. 2017; 16(1):57. PMC: 5341174. DOI: 10.1186/s12943-017-0621-z. View

Chen Y, Zhang S, Wang Q, Zhang X . Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 2017; 10(1):36. PMC: 5286803. DOI: 10.1186/s13045-017-0408-0. View

Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R . Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs. 2022; 31(6):567-591. DOI: 10.1080/13543784.2022.2049232. View

Nolan E, Lindeman G, Visvader J . Deciphering breast cancer: from biology to the clinic. Cell. 2023; 186(8):1708-1728. DOI: 10.1016/j.cell.2023.01.040. View

10.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

11.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26(6):842-844. DOI: 10.1038/s41591-020-0901-9. View

12.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

13.

Guo J, Wei Y, Cen Q, Chen J, Li Y . Developing a novel SARS-CoV-2 risk index to predict the prognostic and therapeutic effects in acute myeloid leukemia. Heliyon. 2023; 9(11):e22426. PMC: 10700646. DOI: 10.1016/j.heliyon.2023.e22426. View

14.

Pathania A, Prathipati P, Abdul B, Chava S, Katta S, Gupta S . COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics. 2021; 11(2):731-753. PMC: 7738845. DOI: 10.7150/thno.51471. View

15.

Ye F, Dewanjee S, Li Y, Jha N, Chen Z, Kumar A . Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023; 22(1):105. PMC: 10324146. DOI: 10.1186/s12943-023-01805-y. View

16.

Fan Y, He L, Wang Y, Fu S, Han Y, Fan J . CLIP4 Shows Putative Tumor Suppressor Characteristics in Breast Cancer: An Integrated Analysis. Front Mol Biosci. 2021; 7:616190. PMC: 7870488. DOI: 10.3389/fmolb.2020.616190. View

17.

Tao S, Chen Q, Lin C, Dong H . Linc00514 promotes breast cancer metastasis and M2 polarization of tumor-associated macrophages via Jagged1-mediated notch signaling pathway. J Exp Clin Cancer Res. 2020; 39(1):191. PMC: 7500027. DOI: 10.1186/s13046-020-01676-x. View

18.

Figueroa J, Gray E, Pashayan N, Deandrea S, Karch A, Vale D . The impact of the Covid-19 pandemic on breast cancer early detection and screening. Prev Med. 2021; 151:106585. PMC: 8241687. DOI: 10.1016/j.ypmed.2021.106585. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Ren X, Wen W, Fan X, Hou W, Su B, Cai P . COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell. 2021; 184(7):1895-1913.e19. PMC: 7857060. DOI: 10.1016/j.cell.2021.01.053. View